GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vivos Inc (OTCPK:RDGL) » Definitions » Net Current Asset Value

Vivos (RDGL) Net Current Asset Value : $0.00 (As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is Vivos Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Vivos's net current asset value per share for the quarter that ended in Sep. 2024 was $0.00.

The historical rank and industry rank for Vivos's Net Current Asset Value or its related term are showing as below:

During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Vivos was 10.18. The lowest was 5.10. And the median was 7.64.

RDGL's Price-to-Net-Current-Asset-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 5.16
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Vivos Net Current Asset Value Historical Data

The historical data trend for Vivos's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivos Net Current Asset Value Chart

Vivos Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 - - - -

Vivos Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vivos's Net Current Asset Value

For the Medical Devices subindustry, Vivos's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivos's Price-to-Net-Current-Asset-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vivos's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Vivos's Price-to-Net-Current-Asset-Value falls into.



Vivos Net Current Asset Value Calculation

Vivos's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(A: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1.61-0.245-0-0.003)/387.894
=0.00

Vivos's Net Current Asset Value (NCAV) per share for the quarter that ended in Sep. 2024 is calculated as

Net Current Asset Value Per Share(Q: Sep. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1.244-0.049-0-0.003)/417.593
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vivos  (OTCPK:RDGL) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Vivos Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Vivos's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivos Business Description

Traded in Other Exchanges
N/A
Address
719 Jadwin Avenue, Richland, WA, USA, 99352
Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising highly insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors. IsoPet is another product of the company used for the treatment of solid tumors in animals. The company derives revenue through sales of its products.
Executives
Michael K Korenko officer: INTERIM CEO AND PRESIDENT 6208 W OKANOGAN AVE, KENNEWICK WA 99336
Michael H Pollack officer: Interim CFO 114 WEST 47TH STREET, 19TH FLOOR, NEW YORK NY 10036
Memorial Institute Battelle 10 percent owner 505 KING AVENUE, COLUMBUS OH 43201
Kenin M. Spivak director 9663 SANTA MONICA BLVD., #1048, BEVERLY HILLS CA 90210
Thomas J Clement director 12445 110TH LANE NE, APT. Q-302, KIRKLAND WA 98034
Leonard Bruce Jolliff officer: Chief Financial Officer 206 N 41ST ST., UNIT 1, YAKIMA WA 98901
Cadwell Family Irrevocable Trust 10 percent owner 909 NORTH KELLOGG STREET, KENNEWICK WA 99336
James C Katzaroff director, 10 percent owner, officer: CEO 719 JADWIN AVE., RICHLAND WA 99352
Bruce Wayne Ratchford director, 10 percent owner 6208 W. OKANOGAN AVE., KENNEWICK WA 99336
Carlton M Cadwell director, 10 percent owner 6208 W OKANOGAN AVE, KENNEWICK WA 99336

Vivos Headlines

From GuruFocus

Vivos Inc Files a New Patent on Precision Radionuclide Therapy Support System Equipment

By Stock market mentor Stock market mentor 01-03-2023

Vivos Inc. Provides Intellectual Property Protection Update

By PurpleRose PurpleRose 07-11-2022

Vivos Inc. Enhances its Intellectual Property Protection

By GuruFocusNews GuruFocusNews 02-24-2022

Vivos Inc. Provides 2021 Recap and Outlines 2022 Objectives

By GuruFocusNews GuruFocusNews 01-24-2022

Vivos Inc Implements Multiple Patient IsoPet� Therapy Day

By GuruFocusNews GuruFocusNews 04-21-2022

Vivos Inc Initiates Isopet� Therapy in Horses

By Marketwired Marketwired 06-24-2021

Vivos Inc. Provides Intellectual Property Protection Update

By GuruFocusNews GuruFocusNews 07-01-2022

Vivos Inc. Provides Intellectual Property Protection Update

By GuruFocusNews GuruFocusNews 05-22-2022

Vivos Inc. Provides Intellectual Property Protection Update

By GuruFocusNews GuruFocusNews 06-21-2022